{
    "clinical_study": {
        "@rank": "68885", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel applied topically, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel applied topically, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel applied topically, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel applied topically."
            }, 
            {
                "arm_group_label": "Treatment Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel applied topically, followed by single-dose 75 mg (1.97 mL) 4% DMSO gel applied topically, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel applied topically, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel applied topically."
            }, 
            {
                "arm_group_label": "Treatment Sequence 3", 
                "arm_group_type": "Experimental", 
                "description": "Single-dose of etoricoxib 150 mg (3.94 mL) 4% DMSO gel applied topically, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel applied topically, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel applied topically, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel applied topically."
            }, 
            {
                "arm_group_label": "Treatment Sequence 4", 
                "arm_group_type": "Experimental", 
                "description": "Single-dose etoricoxib 150 mg (4.30 mL) 4% gel applied topically, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel applied topically, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel applied topically, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel applied topically."
            }, 
            {
                "arm_group_label": "Etoricoxib 50 mg (1.31 mL, 4% DMSO gel)", 
                "arm_group_type": "Experimental", 
                "description": "Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied twice daily to the affected knee for a period of 2 weeks."
            }, 
            {
                "arm_group_label": "Matching Placebo to Etoricoxib 50 mg (1.31 mL, 4% DMSO gel)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Study Part 1 is designed to assess the plasma pharmacokinetics of two different etoricoxib\n      (4%) gel formulations, each at 2 different doses, upon single-dose topical administration on\n      the knee of osteoarthritis participants. Study Part 2 is designed to evaluate the efficacy\n      of topical etoricoxib vs. placebo in the treatment of osteoarthritis of the knee. The\n      primary hypothesis is that at least one of the two gel formulations will be safe and\n      tolerable."
        }, 
        "brief_title": "The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis Pain", 
        "condition_browse": {
            "mesh_term": "Osteoarthritis"
        }, 
        "detailed_description": {
            "textblock": "Part I of the study will consist of a single-dose, open-label, randomized, four-way cross\n      over study with topical administration of etoricoxib gel on the knee of osteoarthritis\n      participants. The washout between successive dose administrations will be at least one week.\n      Part 2 of the study will consist of double-blind, randomized, placebo-controlled, parallel\n      groups, multiple dose, twice daily topical administration of etoricoxib or placebo gel on\n      the knee of osteoarthritis participants for a period of two weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Has diagnosis of osteoarthritis of the knee (tibio-femoral joint) for >6 months based\n             on clinical and radiographic criteria;\n\n          -  Has a diagnosis of American Rheumatology Association (ARA) functional Class I, II, or\n             III;\n\n          -  The knee designated as the \"study joint\" must be the participant's primary source of\n             pain/disability in the lower extremity. If both knees are affected, the most painful\n             joint will be selected for evaluation for inclusion and clinical response;\n\n          -  Female participants of childbearing potential must demonstrate a serum beta human\n             chorionic gonadatropin (\u03b2-hCG) level consistent with a non-gravid state at the\n             screening visit and urine \u03b2-hCG at Day -1 prior to first dosing and agree to use\n             adequate oral or barrier contraception or abstain from sexual contact at least 7 days\n             prior to treatment and continuing through the treatment period or a discontinuation\n             visit;\n\n          -  Willing to limit alcohol intake (beer 8 ounces, wine 4 ounces, liquor 1 ounce) to no\n             more than 14 drinks a week (no more than 2 in a day) and to avoid unaccustomed\n             strenuous physical activity (e.g., unaccustomed weight lifting, initiation of\n             physical therapy) for the duration of the study;\n\n          -  Judged to be in general good health with the exception of osteoarthritis based on\n             medical history, physical examination, and routine laboratory tests.\n\n          -  For Part 2, if the participant is a regular user of non-steroidal anti-inflammatory\n             drugs (NSAIDs) including coxibs he/she must report a history of positive therapeutic\n             benefit in osteoarthritis of the knee with NSAID/coxibs in the past;\n\n          -  For Part 2, participants must be taking a single NSAID on a regular basis and at a\n             prescription strength for at least 30 days prior to study screening (\"regular basis\"\n             is defined as at least 25 of the previous 30 days) for treatment of symptoms of\n             osteoarthritis.\n\n        Exclusion Criteria:\n\n          -  Has a concurrent medical/arthritic disease;\n\n          -  History of acute ligamentous or meniscal injury of the study joint within the\n             previous 2 years or arthroscopy of the affected knee within 6 months prior to study\n             entry;\n\n          -  Is a candidate for imminent joint replacement;\n\n          -  Has clinical or laboratory evidence of significant renal, gastrointestinal,\n             pulmonary, hepatic, endocrine, neurological (apart from migraine), or other systemic\n             disease that in the opinion of the investigator contraindicates the use of\n             etoricoxib;\n\n          -  Has congestive heart failure with symptoms that occur at rest or minimal activity;\n\n          -  Has unstable angina that occurs at rest or with minimal activity;\n\n          -  Has uncontrolled hypertension (sitting diastolic blood pressure >95 mm Hg, or sitting\n             systolic blood pressure >165 mm Hg);\n\n          -  Has a history of stroke or transient ischemic attack (TIA) within the previous 6\n             months;\n\n          -  Has a history of hepatitis/hepatic disease that has been active within the previous 2\n             years;\n\n          -  Has a history of neoplastic disease;\n\n          -  Is currently a user (including \"recreational use\") of any illicit drugs, or has a\n             history of drug or alcohol abuse within the past 5 years;\n\n          -  Is allergic of has hypersensitivity to aspirin, ibuprofen, rofecoxib, celecoxib,\n             valdecoxib, other NSAIDs, acetaminophen, or sulfa drugs;\n\n          -  Has used intravenous, intramuscular, or oral corticosteroids within 1 month of study\n             entry;\n\n          -  Has used glucosamine and/or chondroitin sulfate for <6 months prior to study start;\n\n          -  Has used intra-articular steroids, HYALGAN\u2122 (sodium hyaluronate, Sanofi\n             Pharmaceuticals), or SYNVISC\u2122 (hylan G-F 20, Wyeth-Ayerst Pharmaceuticals) to the\n             study joint within 3 months of entry into the study or intra-articular steroids,\n             HYALGAN\u2122, or SYNVISC\u2122 to any other joint within 1 month of study entry;\n\n          -  Has used topical, oral or systemic analgesic medications within 2 weeks of study\n             entry and for the duration of the study;\n\n          -  Requires treatment with warfarin, heparin, high-dose aspirin (>325 mg), or digoxin;\n\n          -  Has used Arcoxia\u00ae within 2 weeks of study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980940", 
            "org_study_id": "0663-168"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment Sequence 1", 
                "description": "Etoricoxib 75 mg 4% DMSO gel applied topically.", 
                "intervention_name": "Etoricoxib 75 mg 4% DMSO Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment Sequence 2", 
                "description": "Etoricoxib 75 4% PG gel applied topically.", 
                "intervention_name": "Etoricoxib 75 mg 4% PG Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Sequence 3", 
                    "Etoricoxib 50 mg (1.31 mL, 4% DMSO gel)"
                ], 
                "description": "Etoricoxib 150 mg 4% DMSO gel applied topically.", 
                "intervention_name": "Etoricoxib 150 mg 4% DMSO Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Sequence 4", 
                    "Etoricoxib 50 mg (1.31 mL, 4% DMSO gel)"
                ], 
                "description": "Etoricoxib 150 mg 4% PG gel applied topically.", 
                "intervention_name": "Etoricoxib 150 mg 4% PG Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Matching Placebo to Etoricoxib 50 mg (1.31 mL, 4% DMSO gel)", 
                "description": "Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.", 
                "intervention_name": "Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Etoricoxib 50 mg (1.31 mL, 4% DMSO gel)", 
                "description": "Etoricoxib 50 mg (1.31 mL) 4% DMSO gel applied topically.", 
                "intervention_name": "Etoricoxib 50 mg (1.31 mL) 4% DMSO", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dimethyl Sulfoxide", 
                "Etoricoxib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "contact": {
                "last_name": "Tatyana Gots", 
                "phone": "38 044 393-7480"
            }, 
            "facility": {
                "address": {
                    "city": "Chisinau", 
                    "country": "Moldova, Republic of"
                }, 
                "name": "Merck Sharp & Dohme IDEA, Inc."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Moldova, Republic of"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Study to Assess the Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Osteoarthritis Patients", 
        "overall_contact": {
            "last_name": "Toll-Free Number", 
            "phone": "888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Concentration-Time Curve from 0 to Last (AUC 0-last) of MK-0663 in Study Part 1", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 Hours Post-Application"
            }, 
            {
                "measure": "Maximum Plasma Concentration (Cmax) of MK-0663 in Study Part 1", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 Hours Post-Application"
            }, 
            {
                "measure": "Change From Baseline in Mean Participant Score on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Visiual Analog 3.0 Pain Scale in Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980940"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}